Haematologica, Vol 92, Issue 8, 1149-1150 doi:10.3324/haematol.11228
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davies, F. E.
Right arrow Articles by Morgan, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davies, F. E.
Right arrow Articles by Morgan, G. J.

Multiple Myeloma

The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD)

Faith E. Davies, Ping Wu, Matthew Jenner, Muralikrishan Srikanth, Radovan Saso, Gareth J. Morgan

The Royal Marsden Hospital, London, UK

Correspondence: Faith Davies, Haemato-oncology Unit, Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK. Phone: international +44.208.6613670. Fax: international +44.208.6429634. E-mail: faith.davies{at}icr.ac.uk

The combination of bortezomib (velcade), pulsed dexamethasone and weekly cyclophosphamide (CVD) in relapsed/refractory myeloma patients induces high overall (75%) and complete (31%) response rates compared to velcade/dexamethasone (overall 47%, CR 5%) and velcade alone (overall 27%, CR 0%). The toxicity profiles including thrombocytopenia, neutropenia, and neuropathy were comparable between the groups.

Key words: cyclophosphamide, velcade and dexamethasone (CVD), comparable toxicity, high response rates.




This article has been cited by other articles:


Home page
 The OncologistHome page
H. Ludwig, M. Beksac, J. Blade, M. Boccadoro, J. Cavenagh, M. Cavo, M. Dimopoulos, J. Drach, H. Einsele, T. Facon, et al.
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
Oncologist, January 1, 2010; 15(1): 6 - 25.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Q. Lacy, S. R. Hayman, M. A. Gertz, A. Dispenzieri, F. Buadi, S. Kumar, P. R. Greipp, J. A. Lust, S. J. Russell, D. Dingli, et al.
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
J. Clin. Oncol., October 20, 2009; 27(30): 5008 - 5014.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. C. Johnson, S. Corthals, C. Ramos, A. Hoering, K. Cocks, N. J. Dickens, J. Haessler, H. Goldschmidt, J. A. Child, S. E. Bell, et al.
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping
Blood, December 15, 2008; 112(13): 4924 - 4934.
[Abstract] [Full Text] [PDF]